Peripheral zone inflammation is not strongly associated with lower urinary tract symptom incidence and progression in the placebo arm of the prostate cancer prevention trial

Ibrahim Kulac, Berrak Gumuskaya, Charles G. Drake, Beverly Gonzalez, Kathryn B. Arnold, Phyllis J. Goodman, Alan R. Kristal, M. Scott Lucia, Ian M. Thompson, William B Isaacs, Angelo Michael Demarzo, Elizabeth A Platz

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Intraprostatic inflammation has been associated with lower urinary tract symptom (LUTS) progression. However, prior studies used tissue removed for clinical indications, potentially skewing inflammation extent or biasing the association. We, therefore, evaluated inflammation and LUTS incidence and progression in men who underwent biopsy of the prostate peripheral zone irrespective of indication. MATERIALS AND METHODS: We developed nested case-control sets in men in the placebo arm of the Prostate Cancer Prevention Trial who were free of clinical BPH and had a protocol-directed year 7 biopsy. Cases had baseline IPSS 75th percentile (N=46) and controls had a slope 75th percentile (N=46) and controls had a slope

Original languageEnglish (US)
JournalProstate
DOIs
StateAccepted/In press - 2016

Keywords

  • Incidence
  • Inflammation
  • Lower urinary tract symptoms
  • Progression
  • Prostate

ASJC Scopus subject areas

  • Urology
  • Oncology

Fingerprint Dive into the research topics of 'Peripheral zone inflammation is not strongly associated with lower urinary tract symptom incidence and progression in the placebo arm of the prostate cancer prevention trial'. Together they form a unique fingerprint.

Cite this